Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: A case report

Indian Pacing and Electrophysiology Journal

Volumn 11, Issue 3, 2011, Pages 84-88

  Murdock, David K ^a,b   Kaliebe, Jeffrey W ^b  

^a CaRE Foundation Inc   (United States)

^b Aspirus Cardiovascular Associates   (United States)

Author keywords

Cardiac arrhythmias; PVCs; Ranolazine; Triggered activity; Ventricular ectopy

Indexed keywords

AMLODIPINE; FUROSEMIDE; RANOLAZINE;

AGED; ANEMIA; ARTICLE; BRADYCARDIA; CASE REPORT; CLINICAL FEATURE; CONSTIPATION; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DRUG DOSE REDUCTION; DYSPNEA; ECTOPIA CORDIS; ELECTROCARDIOGRAM; EVENING DOSAGE; FATIGUE; FEMALE; HEART ATRIUM ENLARGEMENT; HEART CATHETERIZATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HEART VENTRICLE CONTRACTION; HUMAN; MORNING DOSAGE; SINUS BRADYCARDIA; SYSTOLIC HEART MURMUR;

EID: 79956069812     PISSN: None     EISSN: 09726292     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mitchell LB. Role of drug therapy for sustained ventricular tachyarrhythmias. Cardiol Clin 2008 Aug; 26:405-418.
2. McLenachan JM, Henderson E, Morris KI. Dargie HJ. Ventricular Arrhythmias in Patients with Hypertensive Left Ventricular Hypertrophy. N Engl J Med 1987; 317:787-792.
3. Kannel, WB, Gordon, T, Offutt, D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969; 71:89.
4. Ghali JK, Kadakia S, Cooper RS, Liao YL. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol, 1991; 17:1277-1282.
5. Wolk R. Arrhythmogenic mechanisms in left ventricular hypertrophy. Europace 2000; 2:216-223.
6. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004; 95:754-763.
7. Ebinger MW, Krishnan S, Schuger CD. Mechanisms of ventricular arrhythmias in heart failure. Curr Heart Fail Rep 2005; 2:111-117.
8. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res 2004; 61:208-217.
9. Pogwizd SM, Bers DM. Calcium cycling in heart failure: The arrhythmia connection. J Cardiovasc Electrophysiol 2002; 13:88-91.
10. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 2001; 88:1159-1167.
11. Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J 2006 Suppl A1, A10-A13.
12. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro arrhythmic effects of increasing late Ina in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004; 44:192-199.
13. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, et al. Electrophysiological effects of ranolazine, a novel anti-anginal agent with anti-arrhythmic properties. Circulation 2004; 110:904-910.
14. Undrovinas AI, Belardelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes in dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006; 17 Suppl 1:S169-S177.
15. Murdock DK, Reiffel JA, Kaliebe JW, Larrain G. The Conversion of Paroxysmal or Initial Onset Atrial Fibrillation with Oral Ranolazine: Implications for a New Pill-In-Pocket Approach in Structural Heart Disease. Journal of Atrial Fibrillation 2010:2,705-710.
16. Murdock DK, Kaliebe JW, Overton N. Ranolozine-Induced Suppression of Ventricular Tachycardia in a Patient with Nonischemic Cardiomyopathy: A Case Report. PACE 2008:31, 765-768.
17. Kaliebe JW, Murdock DK. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report. WMJ. 2009 Oct;108:373-5.
18. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanism, incidence, predisposing factors and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-36.
19. Surawicz B. Electrophysiologic substrate of torsades de pointes; dispersion of repolarization or early afterdepolarization? J Am Coll Cardiol 1989;14:172-84.